



**HAL**  
open science

## **Consequences of change in waist circumference on cardio-metabolic risk-factors over 9-years. The D.E.S.I.R. Study**

Beverley Balkau, Eveline Eschwège, Leopold Fezeu, Sylviane Vol, Pascaline Picard,  
The D.E.S.I.R Study Group

### ► **To cite this version:**

Beverley Balkau, Eveline Eschwège, Leopold Fezeu, Sylviane Vol, Pascaline Picard, et al.. Consequences of change in waist circumference on cardio-metabolic risk-factors over 9-years. The D.E.S.I.R. Study. *Diabetes Care*, 2007, 30 (7), pp.1901-1903. <10.2337/dc06-2542>. <inserm-00141337>

**HAL Id: inserm-00141337**

**<https://inserm.hal.science/inserm-00141337v1>**

Submitted on 11 Jul 2007

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

## Consequences of change in waist circumference on cardio-metabolic risk-factors over 9-years. The D.E.S.I.R. Study

---

BEVERLEY BALKAU, PHD<sup>1,2</sup>  
PASCALINE PICARD, MSC<sup>1,2</sup>  
SYLVIANE VOL, MSC<sup>3</sup>  
LEOPOLD FEZEU, MD, MSC<sup>1,2</sup>  
EVELINE ESCHWÈGE, MD<sup>1,2</sup>  
AND THE D.E.S.I.R. STUDY GROUP<sup>3</sup>

---

<sup>1</sup>INSERM U780-IFR69, 16 Avenue Paul Vaillant-Couturier, Villejuif, France.

<sup>2</sup>Univ Paris-Sud, Kremlin Bicêtre, France.

<sup>3</sup>IRSA, La Riche, France

Short running title: Cardio-metabolic effects of 9-year waist change

Text 1009 words

1 table

### CORRESPONDENCE:

Beverley BALKAU

INSERM U780-IFR69

16 Avenue Paul Vaillant-Couturier, 94807 Villejuif, France.

Telephone:33145595161

Fax:33147269454

[balkau@vjf.inserm.fr](mailto:balkau@vjf.inserm.fr)

**Abbreviations:** D.E.S.I.R.,Data from an Epidemiological Study on the Insulin Resistance

Syndrome•NCEP,National Cholesterol Education Program

This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes (<http://diabetes.diabetesjournals.org>). The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version is available online at [DOI of the online article]."

Obesity and abdominal adiposity have been shown to be risk factors for cardiovascular disease and particularly for diabetes in prospective studies (1-8). In cross sectional studies both are related with risk factors for these diseases (9-12), but there are few publications on the effects of changes in abdominal adiposity (13). We characterise men and women who gained and lost abdominal adiposity over nine years and describe the incidence and the improvement in cardio-metabolic risk factors according to changes in waist circumference.

**RESEARCH DESIGN AND METHODS**—From the D.E.S.I.R. cohort (9,14,15), 1868 men, 1939 women, 30-64 years at baseline, were followed over nine years; the 73% of the cohort studied were older, less frequently abdominally obese, hypertriglyceridemic, hyperinsulinemic, smokers and fewer had the metabolic syndrome. Cardio-metabolic abnormalities and the metabolic syndrome were defined according to the NCEP criteria (16), except high blood pressure included anti-hypertensive treatment (Table); hyperinsulinemia was defined by upper quartiles of fasting insulin  $\geq 57.3$ , 52.8 pmol/l (men, women). The incidence and improvement of cardio-metabolic risk factors were studied by age-adjusted logistic regression, according to waist change: ( $\leq -3.0$ cm); (-2.9 to +2.9cm); (+3.0 to +6.9cm); ( $\geq +7.0$ cm). Statistical significance was defined as  $P < 0.05$ .

**RESULTS**—The median increase in waist circumference was 3cm in men, 4cm in women; 25% of men, 34% of women increased their waist by 7cm or more, 14% decreased their waist by 3cm or more, 29% remained stable ( $\pm 2.9$ cm).

Men whose waist decreased were older, with larger waist and BMI at baseline. Age was not significantly related to waist change in women, but women who slimmed had larger baseline waist, but similar BMI. Men who decreased alcohol intake reduced their waist. Stopping smoking was associated with a gain in waist, while smoking at baseline was associated with a gain in waist in men only. Baseline physical activity did not influence waist change, but an increase was associated with a decreasing waist.

The incidence of abdominal obesity was 10% in men, 15% in women (Table). Of all risk factors, high blood pressure had the highest incidence, (48% and 30% respectively) and the incidences of the metabolic syndrome were 8% and 7%. The metabolic syndrome and all cardio-metabolic factors showed significant trends to worsen with an increasing waist (with one exception, LDL-cholesterol in women). The odds ratios (95% CI) for an incident metabolic syndrome were 7.9 (4.4-13.9) in men and 4.7 (2.7-8.0) in women who increased their waist by more than 7cm, compared to a stable waist. Results were not changed after adjusting for baseline waist or BMI. Adjusting for 9-year BMI change, only the metabolic syndrome ( $p < 0.0001$ ) in both sexes and

fasting insulin in women ( $p=0.02$ ) remained statistically significant. Further adjustment for change in smoking habits or physical activity did not alter these associations.

Of those abdominally obese at baseline, 19% of men and 10% of women improved at 9-years (Table). High blood pressure was the abnormality which improved the least. Of those with the metabolic syndrome at baseline, 47% of men and 38% of women no longer had it at 9-years. A decreasing waist was associated beneficially with the syndrome, triglycerides and insulin in both men and women, and blood pressure in women. Further adjustment for baseline waist or BMI did not alter these results, but after adjustment for change in BMI, relations remained significant only in women, for the syndrome, triglycerides and blood pressure. These improvements were not due to starting or continuing drug treatment (data not shown).

**CONCLUSION**—A changing waist affected cardio-metabolic risk factors, and this was most clearly seen for the metabolic syndrome, which accumulates the effects of individual abnormalities: After accounting for changes in BMI, reducing waist by 3cm or more only had a significant beneficial effect on the metabolic syndrome in women, and increasing waist by more than 7cm had a detriment effect in both sexes.

Overall, those who reduced their waist were older and more abdominally obese, and fewer men smoked at baseline. Such men and women might be receptive towards targeted intervention. Further, an increase in physical activity had beneficial effects in our study.

The only other report that we have found on the effects of waist change on risk factors is a 10-year study of Chinese adults (13). Both waist and BMI change, together, were related to change in systolic blood pressure and hypertension. In our European population, a comparable result was only found in the women.

While not all individuals were able to be followed-up, there were no differences in baseline waist nor in changes in waist over 3 and 6 years, with those studied.

An increasing abdominal adiposity was associated with individual cardio-metabolic risk factors, and their aggregation in the metabolic syndrome in both men and women. Unfortunately, a decreasing waistline did not always have a large effect on risk factors, as ageing is also inherent when following populations. The metabolic syndrome was still associated with changing waist circumference after taking account of changing BMI – indicating the importance of this simple clinical measure.

**Acknowledgments**—D.E.S.I.R. Study Group:INSERM U780:B.Balkau,P.Ducimetière,E.Eschwège; INSERM U367:F.Alhenc-Gelas;CHU D'ANGERS:Y.Gallois,A.Girault; HÔPITAL BICHAT:F.Fumeron,M.Marre;

CENTRES D'EXAMENS DE SANTÉ: Alençon, Angers, Caen, Chateauroux, Cholet, Le Mans, Tours; INSTITUT DE RECHERCHE EN MÉDECINE GÉNÉRALE: J. Cogneau; MEDECINS GÉNÉRALISTES des Départements; INSTITUT INTER RÉGIONAL POUR LA SANTÉ: C. Born, E. Cacès, M. Cailleau, J.G. Moreau, F. Rakotozafy, J. Tichet, S. Vol.

The D.E.S.I.R. study has been supported by contracts between INSERM, CNAMTS, Lilly, sanofi-aventis, Novartis Pharma; by INSERM Réseaux en Santé Publique, INSERM Interactions entre les déterminants de la santé, the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon.

P Picard was supported by a grant from sanofi-aventis, France.

We thank I Villadary for her suggestions on the article

## References

1. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G: Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. *BMJ* 288:1401–1404, 1984
2. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE: Abdominal adiposity and coronary heart disease in women. *JAMA* 280:1843–8, 1998
3. Rexrode KM, Buring JE, Manson JE: Abdominal and total adiposity and risk of coronary heart disease in men. *Int J Obes Relat Metab Disord* 25:1047–1056, 2001
4. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS; INTERHEART Study Investigators: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. *Lancet* 366:1640–1649, 2005
5. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, Bjorntorp P, Tibblin G: The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. *Diabetes* 34:1055–1058, 1985
6. Kissebah AH, Peiris AN: Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. *Diabetes Metab Rev* 5:83–109, 1989
7. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, Speizer FE, Manson JE: Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. *Am J Epidemiol* 145:614–619, 1997
8. Wei M, Gaskill SP, Haffner SM, Stern MP: Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans: a 7-year prospective study. *Obes Res* 5:16–23, 1997

9. Bertrais S, Balkau B, Vol S, Forhan A, Calvet C, Marre M, Eschwege E: Relationships between abdominal body fat distribution and cardiovascular risk factors: an explanation for women's healthier cardiovascular risk profile. The D.E.S.I.R. Study. *Int J Obes Relat Metab Disord* 23:1085-1094, 1999
10. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. *Arteriosclerosis* 10:497-511, 1990
11. Stolk RP, Suriyawongpaisal P, Aekplakorn W, Woodward M, Neal B; InterASIA Collaborative Group: Fat distribution is strongly associated with plasma glucose levels and diabetes in Thai adults-the InterASIA study. *Diabetologia* 48:657-660, 2005
12. Canoy D, Luben R, Welch A, Bingham S, Wareham N, Day N, Khaw KT: Fat distribution, body mass index and blood pressure in 22,090 men and women in the Norfolk cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) study. *J Hypertens* 22:2067-2074, 2004
13. Chuang SY, Chou P, Hsu PF, Cheng HM, Tsai ST, Lin IF, Chen CH: Presence and progression of abdominal obesity are predictors of future high blood pressure and hypertension. *Am J Hypertens* 19:788-795, 2006
14. Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, Tichet J, Eschwege E; D.E.S.I.R. Study Group: The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. *Diabetes Metab* 29:526-532, 2003
15. Hillier TA, Fagot-Campagna A, Eschwege E, Vol S, Cailleau M, Balkau B; the D.E.S.I.R. Study group: Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the D.E.S.I.R. cohort. *Int J Epidemiol* 35:190-196, 2006
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 285:2486-2497, 2001

**Table—Age-adjusted odds ratios of the incidence of cardio-metabolic parameters according to change in waist circumference group; p-values for trend, adjusted for age. The D.E.S.I.R. Study**

Men	incidence	≤ -3 cm n=250	-2.9 to +2.9 cm n=542	3 to 6.9cm n=488	≥ 7 cm n=659	P-value trend
<b>INCIDENCE</b>						
Waist > 102 cm	177/1716=10%	no cases	1	<b>5.00 (4.29-10.0)</b>	<b>21.25 (10.9-41.2)</b>	<.0001
Glucose ≥ 6.1 mmol/l	121/1583=8%	0.79 (0.40-1.57)	1	1.18 (0.72-1.94)	<b>1.68 (1.03-2.72)</b>	.01
Blood pressures ≥ 130/85 mmHg or treated for hypertension	276/579=48%	0.58 (0.32-1.07)	1	0.93 (0.61-1.42)	1.49 (0.95-2.33)	.008
Triglycerides ≥ 1.7 mmol/l	181/1498=12%	0.78 (0.42-1.44)	1	1.21 (0.78-1.86)	<b>2.29 (1.53-3.44)</b>	<.0001
HDL cholesterol < 1.03 mmol/l	94/1738=5%	0.64 (0.27-1.50)	1	1.39 (0.79-2.42)	<b>1.97 (1.14-3.41)</b>	.001
LDL cholesterol ≥ 4.13 mmol/l	240/1280=19%	0.85 (0.51-1.41)	1	1.23 (0.85-1.78)	1.39 (0.96-2.02)	.02
Insulin ≥ 57.3 pmol/l	492/1401=35%	0.67 (0.45-1.00)	1	<b>1.57 (1.18-2.09)</b>	<b>2.33 (1.73-3.14)</b>	<.0001
NCEP metabolic syndrome	135/1693=8%	0.57 (0.19-1.72)	1	<b>2.39 (1.28-4.44)</b>	<b>7.87 (4.46-13.88)</b>	<.0001
<b>IMPROVEMENT</b>						
Waist ≤ 102 cm	29/152=19%	<b>32.1 (6.84-151)</b>	1	no cases	no cases	<.0001
Glucose < 6.1 mmol/l	137/285=48%	0.69 (0.34-1.41)	1	0.62 (0.33-1.15)	0.69 (0.36-1.32)	0.5
Blood pressures < 130 and 85 mmHg and not treated for hypertension	213/1289=17%	1.03 (0.66-1.63)	1	0.77 (0.52-1.14)	0.76 (0.50-1.14)	.09
Triglycerides < 1.7 mmol/l	187/370=51%	0.95 (0.50-1.81)	1	0.81 (0.48-1.38)	<b>0.45 (0.25-0.81)</b>	.01
HDL cholesterol ≥ 1.03 mmol/l	71/130=55%	1.25 (0.37-4.20)	1	0.55 (0.21-1.46)	0.74 (0.30-1.84)	.3
LDL cholesterol < 4.13 mmol/l	288/588=49%	1.35 (0.82-2.22)	1	0.91 (0.59-1.40)	1.09 (0.69-1.72)	.5
Insulin < 57.3 pmol/l	101/467=22%	1.45 (0.78-2.70)	1	0.93 (0.54-1.62)	<b>0.27 (0.13-0.57)</b>	<.0001
No NCEP metabolic syndrome	83/175=47%	0.93 (0.41-2.12)	1	0.59 (0.27-1.32)	<b>0.38 (0.16-0.91)</b>	.03

<b>Women</b>	<b>incidence</b>	<b>≤ -3 cm</b> n=250	<b>-2 to +2.9 cm</b> n=542	<b>3 to 6.9cm</b> n=488	<b>≥ 7 cm</b> n=659	<b>P-value</b> trend
<b>Odds ratios</b>						
<b>INCIDENCE</b>						
Waist > 88 cm	250/1679=15%	no cases	1	<b>7.91 (3.52-17.8)</b>	<b>39.4 (18.2-85.1)</b>	<.0001
Glucose ≥ 6.1 mmol/l	73/1845=4%	0.28 (0.06-1.24)	1	0.83 (0.38-1.83)	<b>2.72 (1.49-4.96)</b>	<.0001
Blood pressures ≥ 130/85 mmHg or treated for hypertension	306/1013=30%	1.18 (0.72-1.94)	1	<b>1.53 (1.04-2.23)</b>	<b>1.52 (1.07-2.17)</b>	.0370
Triglycerides ≥ 1.7 mmol/l	140/1784=8%	1.11 (0.57-2.17)	1	1.14 (0.66-1.96)	<b>2.23 (1.40-3.54)</b>	.0006
HDL cholesterol < 1.29 mmol/l	193/1759=11%	0.70 (0.38-1.31)	1	1.09 (0.70-1.69)	<b>1.88 (1.29-2.75)</b>	<.0001
LDL cholesterol ≥ 4.13 mmol/l	294/1552=19%	0.82 (0.52-1.30)	1	0.80 (0.56-1.15)	<b>1.13 (0.82-1.55)</b>	0.2
Insulin ≥ 52.8 pmol/l	479/1455=33%	0.71 (0.47-1.09)	1	1.21 (0.89-1.65)	<b>2.55 (1.92-3.38)</b>	<.0001
NCEP metabolic syndrome	131/1815=7%	0.48 (0.16-1.45)	1	1.28 (0.67-2.45)	<b>4.69 (2.77-7.93)</b>	<.0001
<b>Odds ratios</b>						
<b>IMPROVEMENT</b>						
Waist ≤ 88 cm	29/260=10%	<b>54.9 (7.09-426)</b>	1	no cases	no cases	<.0001
Glucose < 6.1 mmol/l	35/94=37%	0.29 (0.07-1.24)	1	<b>0.23 (0.07-0.83)</b>	0.44 (0.14-1.37)	0.7
Blood pressures < 130 and 5 mmHg and not treated for hypertension	196/926=21%	0.90 (0.54-1.49)	1	0.66 (0.42-1.03)	<b>0.37 (0.23-0.57)</b>	<.0001
Triglycerides < 1.7 mmol/l	93/155=60%	1.78 (0.61-5.18)	1	0.64 (0.26-1.62)	0.45 (0.20-1.03)	.008
HDL cholesterol ≥ 1.29 mmol/l	82/180=46%	2.53 (0.94-6.82)	1	0.84 (0.33-2.15)	1.43 (0.63-3.23)	0.4
LDL cholesterol < 4.13 mmol/l	217/387=56%	1.00 (0.54-1.87)	1	0.92 (0.53-1.62)	0.81 (0.48-1.37)	0.4
Insulin < 52.8 pmol/l	109/484=23%	1.31 (0.69-2.50)	1	0.67 (0.36-1.22)	0.47 (0.27-0.81)	.0005
No NCEP metabolic syndrome	47/124=38%	<b>3.78 (1.28-11.13)</b>	1	0.45 (0.14-1.50)	<b>0.68 (0.25-1.87)</b>	.003